Simpson E, Farrant J, Chandler P
Transplantation Biology Section, Clinical Research Centre, Harrow, Middlesex, U.K.
Immunol Rev. 1991 Dec;124:97-111. doi: 10.1111/j.1600-065x.1991.tb00618.x.
CB.17 mice homozygous for the scid defect have been used as recipients of peripheral blood lymphocytes (PBL) from normal humans and from patients suffering from common variable immunodeficiency (CVI) types A and B. Following intra-peritoneal injection of PBL, such mice become chimeric with human cells, as evidenced by the presence in their serum of human immunoglobulins, which persist for a number of months. Under these conditions, B cells from CVI patients are also triggered to produce immunoglobulin. In contrast, T cells in the inocula, although they persist for 1 or 2 months in the peritoneal cavity, do not appear to function normally in antigen-specific responses and they do not recirculate in the recipient mice.
纯合scid缺陷的CB.17小鼠已被用作正常人以及患有A、B型常见变异型免疫缺陷（CVI）患者外周血淋巴细胞（PBL）的受体。腹腔注射PBL后，这些小鼠与人细胞形成嵌合体，其血清中存在人免疫球蛋白可证明这一点，这种情况会持续数月。在这些条件下，CVI患者的B细胞也会被触发产生免疫球蛋白。相比之下，接种物中的T细胞虽然在腹腔中持续存在1或2个月，但在抗原特异性反应中似乎不能正常发挥作用，也不会在受体小鼠中再循环。
